Paper39606232
The role of miR-152 in urological tumors: potential biomarkers and therapeutic targets.
Li X and 6 others. Front Immunol, 2024. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. The role of miR-152 in urological tumors: potential biomarkers and therapeutic targets. Papers, record 39606232. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39606232
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| MicroRNAs | Major topic |
| Biomarkers, Tumor | Major topic |
| Gene Expression Regulation, Neoplastic | Major topic |
| Urologic Neoplasms | Major topic |
| Humans | |
| Male | |
| Animals | |
| Prostatic Neoplasms | |
| Urinary Bladder Neoplasms |
Source PubMed
References130
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34936728 | METTL1-m7 G-EGFR/EFEMP1 axis promotes the bladder cancer development. | Clin Transl Med | 2021 | https://conductscience.org/library/papers/34936728 | PubMed |
| 2 | 25190353 | MiR-152 suppresses the proliferation and invasion of NSCLC cells by inhibiting FGF2. | Exp Mol Med | 2014 | https://conductscience.org/library/papers/25190353 | PubMed |
| 3 | 35236289 | miR-152-3p impedes the malignant phenotypes of hepatocellular carcinoma by repressing roundabout guidance receptor 1. | Cell Mol Biol Lett | 2022 | https://conductscience.org/library/papers/35236289 | PubMed |
| 4 | 29723452 | [Circulating miR-152 helps early prediction of postoperative biochemical recurrence of prostate cancer]. | Zhonghua Nan Ke Xue | 2017 | https://conductscience.org/library/papers/29723452 | PubMed |
| 5 | 20146264 | MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. | Hepatology | 2010 | https://conductscience.org/library/papers/20146264 | PubMed |
| 6 | 33405070 | Lumasiran: First Approval. | Drugs | 2021 | https://conductscience.org/library/papers/33405070 | PubMed |
| 7 | 31038865 | lncRNA CCAT1 promotes bladder cancer cell proliferation, migration and invasion. | Int Braz J Urol | 2019 | https://conductscience.org/library/papers/31038865 | PubMed |
| 8 | 33732021 | LncRNA HCG18 Promotes Clear Cell Renal Cell Carcinoma Progression by Targeting miR-152-3p to Upregulate RAB14. | Cancer Manag Res | 2021 | https://conductscience.org/library/papers/33732021 | PubMed |
| 9 | 37625835 | miR-152-3p Inhibits Proliferation, Invasion and Autophagy in UMUC3 and TCCSUP Bladder Cancer Cell Lines via Suppressing HMGA2 Expression. | Ann Clin Lab Sci | 2023 | https://conductscience.org/library/papers/37625835 | PubMed |
| 10 | 12198168 | MicroRNA maturation: stepwise processing and subcellular localization. | EMBO J | 2002 | https://conductscience.org/library/papers/12198168 | PubMed |
| 11 | 23460133 | miR-152 controls migration and invasive potential by targeting TGFα in prostate cancer cell lines. | Prostate | 2013 | https://conductscience.org/library/papers/23460133 | PubMed |
| 12 | 33500248 | A lncRNA TCL6-miR-155 Interaction Regulates the Src-Akt-EMT Network to Mediate Kidney Cancer Progression and Metastasis. | Cancer Res | 2021 | https://conductscience.org/library/papers/33500248 | PubMed |
| 13 | 23958847 | MicroRNA signature helps distinguish early from late biochemical failure in prostate cancer. | Clin Chem | 2013 | https://conductscience.org/library/papers/23958847 | PubMed |
| 14 | 21221794 | miR-137 is frequently down-regulated in gastric cancer and is a negative regulator of Cdc42. | Dig Dis Sci | 2011 | https://conductscience.org/library/papers/21221794 | PubMed |
| 15 | 35907137 | TMEM97 is transcriptionally activated by YY1 and promotes colorectal cancer progression via the GSK-3β/β-catenin signaling pathway. | Hum Cell | 2022 | https://conductscience.org/library/papers/35907137 | PubMed |
| 16 | 38223603 | Expression of miR-152 in cervical cancer and its influence on cisplatin resistance. | Afr Health Sci | 2023 | https://conductscience.org/library/papers/38223603 | PubMed |
| 17 | 38572751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 18 | 26155421 | Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma. | Oncoimmunology | 2015 | https://conductscience.org/library/papers/26155421 | PubMed |
| 19 | 15531879 | Processing of primary microRNAs by the Microprocessor complex. | Nature | 2004 | https://conductscience.org/library/papers/15531879 | PubMed |
| 20 | 30845775 | Assessment of miR-98-5p, miR-152-3p, miR-326 and miR-4289 Expression as Biomarker for Prostate Cancer Diagnosis. | Int J Mol Sci | 2019 | https://conductscience.org/library/papers/30845775 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41462933 | Differentially Expressed miRNA of Prostate Cancer Compared with Benign Prostatic Hyperplasia Tissues: VAMP Associated Protein B Could Be Used for New Targets and Biomarkers of Prostate Cancer. | Biomedicines | 2025 | https://conductscience.org/library/papers/41462933 | PubMed |
| 40643721 | Regulation and function of microRNA-152 in various types of cancers: its upstream regulators and downstream targets. | Clin Exp Med | 2025 | https://conductscience.org/library/papers/40643721 | PubMed |
| 40309956 | Mechanism of microRNA-152 Regulating Decidual Natural Killer Cell Viability and Affecting Trophoblast Cell Invasiveness via the HLA-G/KIR2DL4 Axis. | Kaohsiung J Med Sci | 2025 | https://conductscience.org/library/papers/40309956 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| MIR152 | 406943 | PubTator's text mining | https://conductscience.org/library/genes/406943 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39606232
GET https://conductscience.org/api/papers/v1/39606232/references?page=2